Study of PYX-106 in Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

PYX-106

Intravenous (IV) infusion

Trial Locations (20)

1200

Cliniques Universitaires Saint-Luc, Brussels

3000

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven

6000

Grand Hôpital de Charleroi - Notre Dame, Charleroi

9000

Universitair Ziekenhuis Gent, Ghent

22031

NEXT Virginia, Fairfax

28040

START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

HM Centro Integral Oncológico Clara Campal, Madrid

30322

Winship Cancer Institute of Emory University, Atlanta

44718

Gabrail Cancer and Research Center, Canton

46010

Hospital Clínico Universitario de Valencia, Valencia

60637

University of Chicago Medicine, Chicago

75039

NEXT Oncology, Irving

80218

SCRI- HealthOne Denver, Denver

85258

HonorHealth Research Institute, Scottsdale

90033

University of Southern California, Los Angeles

92093

University of California San Diego, La Jolla

02215

Dana-Farber Cancer Institute, Boston

02906

Lifespan - Rhode Island Hospital, Providence

08028

Hospital Universitari Dexeus, Barcelona

All Listed Sponsors
lead

Pyxis Oncology, Inc

INDUSTRY

NCT05718557 - Study of PYX-106 in Solid Tumors | Biotech Hunter | Biotech Hunter